Armata Pharmaceuticals (ARMP) Liabilities and Shareholders Equity (2013 - 2026)

Armata Pharmaceuticals has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $69.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 20.0% year-over-year to $69.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $317.0 million (down 16.63% YoY) and the FY2025 annual result came in at $76.9 million, down 11.05% from the prior year.
• Liabilities and Shareholders Equity retreated to $69.8 million in Q1 2026 per ARMP's latest filing, from $76.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $120.4 million in Q1 2024 and troughed at $69.8 million in Q1 2026.
• A 5-year average of $96.2 million and a median of $98.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 117.67% in 2022, then dropped 27.51% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $95.8 million in 2022, then rose by 2.64% to $98.4 million in 2023, then fell by 12.12% to $86.4 million in 2024, then fell by 11.05% to $76.9 million in 2025, then fell by 9.21% to $69.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $69.8 million, $76.9 million, and $89.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.